Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.07.297
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective

BMC Health Services Research
Health Policy
2015English

Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost Effectiveness Evaluation of Canagliflozin in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin in the Treatment of Type 2 Diabetes Mellitus From a Turkish Healthcare Perspective

Journal of Diabetes & Metabolism
2017English

Cost-Utility Analysis of Liraglutide Compared With Sulphonylurea or Sitagliptin, All as Add-On to Metformin Monotherapy in Type 2 Diabetes Mellitus

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Comparison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients

Journal of Young Pharmacists
ToxicologyPharmaceuticsPharmacology
2017English

Metformin as First-Line Treatment for Type 2 Diabetes

The Lancet
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy